New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 14, 2012
10:55 EDTABT, ABT, CELG, CELG, GILD, GILD, INFI, INFI, PCYC, PCYC, PFE, PFE, RHHBY, RHHBY, SGEN, SGENLeerink's biotech analyst holds a post-ASH update conference call
Biotech Analyst Liang discusses new agents for lymphomas including new data on kinase inhibitors Ibrutinib (PCYC), GS-1101 (GILD), IPI-145 (INFI), Bcl-2 inhibitor ABT-199 (ABT/Roche) on the Analyst/Industry conference call to be held on December 14 at 11 am.
News For ABT;CELG;GILD;INFI;PCYC;PFE;RHHBY;SGEN From The Last 14 Days
Check below for free stories on ABT;CELG;GILD;INFI;PCYC;PFE;RHHBY;SGEN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
July 23, 2014
10:27 EDTABTHouse Energy & Commerce Committee to hold a hearing
Subscribe for More Information
09:41 EDTCELGActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL NFLX FB MSFT CELG TWTR TSLA VALE CNW
09:08 EDTRHHBYUltragenyx appoints Sunil Agarwal, M.D. as Chief Medical Officer
Subscribe for More Information
06:45 EDTABTLawmakers divided on inversion deals, NY Times says
Subscribe for More Information
July 22, 2014
16:18 EDTPFEPuma Biotech now responsible for R&D expenses associated with legacy trials
Subscribe for More Information
07:12 EDTCELGCelgene has upper hand in Revlimid case, says Bernstein
Subscribe for More Information
06:14 EDTGILDGilead July weekly volatility elevated into Q2
Subscribe for More Information
05:21 EDTRHHBYRoche announces Genentech Avastin granted priority review by FDA
Subscribe for More Information
July 21, 2014
16:00 EDTGILDOptions Update; July 21, 2014
iPath S&P 500 VIX Short-Term Futures up 65c to 28.53. Option volume leaders: AAPL FB NFLX DG CMCSA GILD PBR TWTR TSLA according to Track Data.
09:38 EDTGILDActive equity options trading on open
Subscribe for More Information
07:21 EDTGILDGilead could be hurt by new HCV drugs, says Wells Fargo
Noting that data on a new Merck (MRK) HCV treatment is expected in November, Wells Fargo thinks Merck's HCV drug could be combined with Gilead's (GILD) Sovaldi to shorten the duration of treatment to four weeks. Other companies could take similar actions, and Gilead's per patient revenues would be significantly reduced if this occurs, the firm warned. However, it continues to have an upbeat outlook on Gilead heading into what it sees as a strong quarter and is still upbeat on the company's long-term HCV opportunity. It keeps an Outperform rating on Gilead.
07:11 EDTRHHBYInternational Society of DNA Vaccines to hold a conference
Subscribe for More Information
06:43 EDTGILD, RHHBYGrowing market for hepatitis-C treatment prompts legal scramble, WSJ says
Subscribe for More Information
July 20, 2014
15:42 EDTRHHBYRoche not looking for big acquisitions, Reuters says
Subscribe for More Information
12:46 EDTGILDGilead drug cocktail helps treat HIV/HCV-coinfected patients, JAMA says
Subscribe for More Information
July 18, 2014
16:47 EDTABTMarket ends week higher as earnings, M&A offset geopolitical tensions
Subscribe for More Information
12:51 EDTABTKey GOP senator signals readiness for inversion deal, The Hill says
Subscribe for More Information
July 17, 2014
17:42 EDTRHHBYCepheid says Roche patent suit will not have material adverse impact on results
Subscribe for More Information
08:08 EDTPFEBristol-Myers, Pfizer announce enrollment in Phase IV EMANATE trial for Eliquis
Subscribe for More Information
07:06 EDTABTAbbott price target raised to $47 from $42 at Stifel
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use